A well-educated 61-year-old lady of South Asian origin was referred to the community mental health team (CMHT) by the accident and emergency (A&E) liaison psychiatry team with delusions, agitation and paranoia. She had a 10-year history of idiopathic PD, and no other physical health issues. Apart from some counselling for low mood which she received when she was first diagnosed with PD, she did not have any mental health issues. There was no known family history of mental illness.
She presented to A&E after upturning the family home in her distressed state. She was experiencing delusional misidentification and was convinced that her son and husband were not who they said they were. When challenged about this, she said that they appeared to have the same features as her husband and son, but looked different, somehow younger or behaving and speaking in a different way. She also complained of painful stiffness in her legs that worsened when they were in the house. She was convinced this was not part of her PD, but rather, felt that an external force was coiling and tightening around her legs.
Over the previous 3 months, her family had been concerned about subtle personality changes, and had mentioned this to their GP, who was in contact with the neurologist. Together, they had initiated some cautious reductions to her anti-PD medications, and also organised for her to be assessed for a deep brain stimulation (DBS) device.
At the time of referral to the CMHT, her medications were Stalevo (levodopa, carbidopa and entacapone), Sinemet CR (carbidopa and levodopa), Requip (ropinirole), Azilect (rasagiline), amantadine and Madopar (benserazide and levodopa). Despite thorough investigation, no organic cause was identified for her delirium. On examination, there was no obvious parkinsonism and her cognition was intact. In addition, as part of the assessment for DBS, she had had a recent neuropsychology assessment that was within normal limits.
Despite aggressive reduction of her anti-PD drugs to just Stavelo, her mental state did not improve. The patient was offered admission to the local mental health unit for safe medication management, but declined. The risks of community management were discussed with the patient, as well as her family, who agreed to provide extra support at home. The CMHT introduced a small dose of the atypical anti-psychotic quetiapine, starting at 12.5 mg at night, titrating to 100 mg at night based on clinical response and side effects. The crisis management team were in daily contact with her and her family, and she had her mental state reviewed by a doctor from the team at least once a week,. There was also close email and telephone communication between the CMHT, the PD team and her GP.
This resulted in slow but steady improvement. Nine months after the onset of her psychosis, she is free of delusions, with retrospective insight, and starting to resume her previous level of activity. Of note, during the initial period of aggressive medication reduction, she had described worsening mobility, however, there was never any objective parkinsonism. Psychotic symptoms in PD range from mild hallucinations with retained insight to severe paranoid delusional states. The most common symptoms are visual hallucinations (25-33%), followed by auditory hallucinations (20%), delusions (5%) and paranoid ideation (4.6%). Delusions are more common in younger age groups, and in druginduced psychosis (Lee & Weintraub, 2012) .
Drug-induced psychosis is regarded as the most common cause of psychosis in PD. While it is widely accepted that this is caused by the dopaminergic nature of anti-PD medications, the exact pathophysiology has not been conclusively proven. The most commonly held hypothesis is that this is due to hypersensitisation of dopamine ... ................................................................................................................................................................................................ receptors following chronic stimulation by dopaminergic drugs. In drug-induced psychosis, it is thought that this occurs particularly in the limbic structures, which are ordinarily responsible for creating emotional significance to external sensory input. Hence, internal stimuli, such as PD symptoms, can be misattributed to having originated from the external world, particularly if this external stimuli that carries emotional meaning (Latoo, Mistry, & Dunne, 2012) . In this case, the patient was convinced that her mobility issues were caused by an external force, and not her PD. In addition, she was also misidentifying her son and husband's facial features, two people to whom she had clear emotional attachment.
Other lesser-held theories for psychosis in PD include visual processing deficits, fragmented REM sleep, indirect dopaminergic neurochemical abnormalities, Lewy body deposition in the temporal lobes, and genetic predisposition (Latoo et al., 2012) .
The management of psychosis in PD is guided by best practice consensus as opposed to formalised guidelines. The first step is to exclude other organic causes of psychosis (including delirium); Lewy body dementia is also more likely if the patient has had PD for less than 1 year. Pharmacological management involves the reduction of anti-PD drugs, and the introduction of anti-psychotics if required. It is generally accepted that anti-PD medications are reduced in this order: anti-cholinergics, selegiline, amantidine, dopamine-agonists, catechol-Omethyl transferase (COMT) inhibitors, levodopa.
It is likely the patient will require a small dose of an antipsychotic, and the choices are relatively limited to those anti-psychotics with minimal extra-pyramidal side effects. These are: quetiapine, clozapine and aripiprazole. The initiation of clozapine in the community setting may be challenging as it is a named patient drug and requires regular blood monitoring due to the risk of agranulocytosis. Cholinesterase inhibitors are very useful if PD dementia is concurrent (Zahodne & Fernandez, 2008) .
Non-pharmacological management involves the consideration of electroconvulsive therapy (Latoo et al., 2012) and DBS to reduce the dose of dopaminergic medication required (Factor et al., 2003) . Of course, the involvement of the multidisciplinary team is very important.
With increasing bed shortages in acute mental health trusts, this case illustrates that a safe clinical outcome is possible in the community even for a patient who is acutely psychotic. In the past this lady may have been admitted in her best interest, as her risk level may have been considered too high to manage in the community. However, multiple community health teams (primary care, mental health, neurology) came together, along with the invaluable support of her family, to facilitate her improvement in the community.
